First Tracks Biotherapeutics (NASDAQ:TRAX – Get Free Report) was upgraded by stock analysts at Wells Fargo & Company to a “strong-buy” rating in a research note issued on Monday,Zacks.com reports.
Other equities analysts have also recently issued research reports about the company. Wall Street Zen upgraded First Tracks Biotherapeutics to a “hold” rating in a report on Saturday, May 2nd. HC Wainwright started coverage on First Tracks Biotherapeutics in a report on Tuesday, April 28th. They issued a “buy” rating and a $30.00 target price for the company. Wedbush started coverage on First Tracks Biotherapeutics in a report on Friday, April 24th. They issued an “outperform” rating and a $30.00 target price for the company. Zacks Research upgraded First Tracks Biotherapeutics to a “hold” rating in a report on Monday, April 27th. Finally, Barclays started coverage on First Tracks Biotherapeutics in a report on Wednesday, April 22nd. They issued an “overweight” rating and a $40.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $38.25.
Get Our Latest Stock Report on First Tracks Biotherapeutics
First Tracks Biotherapeutics Stock Performance
Featured Articles
- Five stocks we like better than First Tracks Biotherapeutics
- Campbell’s Soup Stock: Deep Value and a 7% Dividend Yield
- 3 Stocks With Fresh Catalysts to Watch Before the July 4
- Amprius Insiders Are Selling: Should Investors Be Worried?
- A Weaker Dollar Could Put These 3 Industrial Stocks Back in Focus
Receive News & Ratings for First Tracks Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for First Tracks Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
